No new treatments for schizophrenia have been approved in nearly three decades ... The company is currently studying the drug in Alzheimer’s-related psychosis, and next year plans to start late-stage ...

Brain diagnostics company Amprion recently closed $6 million from a $15 million total Series B financing round to expand the company's commercial reach ...

Cassava then released the altered data in a press release and investor deck, which led the SEC to allege that the company and ...

Roughly 82 percent of Americans support requiring Medicare and insurance companies to cover the Alzheimer's treatments.

Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain ...

Geroscience has a long way to go, but there are four FDA-approved drugs that have shown promise to “target the process of ...

Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients ...

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness ...

Caris said MI Cancer Seek will be used as a companion diagnostic to identify cancer patients who may benefit from treatment ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

New treatments for Alzheimer disease don’t reverse cognitive symptoms, but they do significantly slow progression. Evidence suggests that earlier treatment is most effective.

With new therapies available to treat early stages of Alzheimer disease, recognizing the symptoms earlier is increasingly important.